Primer on Diabetes Management

Symposium on Diabetes and Cancer 2017: Novel Links and Treatments

S. Inzucchi

Diabetes Treatment Guidelines Finally Have Entered the 21st Century …

ASPC 2019 Congress on CVD Prevention

R. DeFronzo

GLP-1/GIP Update: Stay Tuned... The Best is Yet to Come!!

Robert Busch

SURPASS 2: Tirzepatide Versus Once-Weekly Semaglutide

Juan Frias

Labs to Check on Semaglutide or Tirzepatide

Susan Brian

MAFLD: What Is It?

Houston Methodist

D. Victor

SGLT2 Inhibitors, GLP1 Receptor Agonists, and Renal Outcomes

Cardiometabolic Health Congress (CMHC)

L. Sloan

Could GLP-1's be a 'Game Changer' For Weight Loss? Can it be a Safer…

Ken Fujioka

Weightloss in Menopause

Susan Brian

Tirzepatide Updates

Diana Isaacs

Endoscopic Weight Loss Therapies - A Paradigm Shift in the Treatment…

Houston Methodist

T. R. Mccarty

Incretin-based Therapies in the Management of Obesity and its Comorb…

Michigan Medicine

A. Rothberg

The Differences Between the Products of GLP1's and GLP/GIPs

Susan Brian

Discussing Retatrutide: A GIP, GLP-1, and Glucagon Receptor Agonist

Susan Brian

Tirzepatide for Type 2 Diabetes

Diana Isaacs

Current Treatment of Metabolic Dysfunction Associated with Steatotic…

Indiana University School of Medicine Division of Gastroenterology and Hepatology

N. Samala

Practice Guidelines Based Approach to Hereditary Hemochromatosis

MUSC Health

K. Kowdley

GLP-1 Hysteria

Scripps Health

S. Harris

New Research: Side Effect of GLP1

Susan Brian

Obesity: A Serious Cardiovascular Risk Factor? A Review of GLP-1 Rec…

Scripps Health

L. Vincent